Ticker
WOCKPHARMA
Analysis
Wockhardt Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to WOCKPHARMA.
Wockhardt Limited investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to WOCKPHARMA.
WOCKPHARMA
Stock
$3.42B
Health Technology
Pharmaceuticals: Major
INR
Wockhardt Limited may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
Wockhardt today announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of a...
Wockhardt Limited has informed the Exchange regarding a press release dated May 29, 2026, titled " Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a ...
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to Wockhardt's breakthrough ant...
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated) for the quarter and the fi...
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's...
Review valuation context for Wockhardt Limited.
Review future growth context for Wockhardt Limited.
Review past performance context for Wockhardt Limited.
Review financial health context for Wockhardt Limited.
Review dividend context for Wockhardt Limited.
Review management context for Wockhardt Limited.
Review ownership context for Wockhardt Limited.
Review other information context for Wockhardt Limited.
Review community context for Wockhardt Limited.